BMO Capital initiated coverage of Medpace (MEDP) with a Market Perform rating and $600 price target The firm views the stock’s valuation as full in a “tepid” biotech funding backdrop. The shares at current levels leave “little cushion for additional potential macro volatility,” the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace Holdings Inc: Key Update on the OPAL Study for Lymphoid Malignancies
- Medpace and AVM Biotechnology’s Promising ARDS Study: A Potential Game Changer
- Medpace and Telix Collaborate on Promising Phase 3 Study for Advanced Kidney Cancer
- Medpace and Radiopharm Launch Promising Cancer Study with 177LuBetaBart
- Medpace and Radiopharm Theranostics Advance Brain Metastases Imaging Study